Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and...
Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic...
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment...